title: Prognosis for papillary serous carcinoma of the endometrium after surgical staging.
abstract: BACKGROUND
  To investigate the pattern of failure and the prognosis following pathological staging for uterine papillary serous carcinoma (UPSC).
  
  
  METHODS
  A retrospective review was conducted of 22 patients with UPSC, treated between 1989 and 1998 at a single institution. All patients were surgically staged. Two patients with advanced disease received chemotherapy only. Two patients with early-stage disease were followed without further treatment. Eighteen patients received postoperative irradiation; eight patients received whole abdominal irradiation (WART), and the remaining 10 patients, pelvic irradiation (PRT). In addition, seven of these patients received vaginal cuff irradiation with low-dose-rate or high-dose-rate brachytherapy. Toxicity, pattern of failure, and survival were evaluated and compared to the literature.
  
  
  RESULTS
  Seven patients (32%) developed distant metastases, three out of seven (42%) after WART. Four out of seven patients who had distant metastases died from disease progression during subsequent chemotherapy. All patients with distant metastases had locally advanced-stage disease at presentation (six stage III, one stage IV). Four patients with pelvic recurrences developed concurrent (2) and subsequent (2) distant metastases. Three patients had isolated distant metastases. No patient with early stage-disease (stage I and II) died from disease progression.
  
  
  CONCLUSIONS
  Pathological staging should be performed for all patients with UPSC to determine the prognosis as well as to tailor the treatment. The role of abdominal irradiation in the treatment of UPSC is yet to be determined; however, such an approach may not be necessary for the control of disease for patients with early-stage (I and II) disease. Patients with locally advanced-stage (stage III) disease are at risk of local regional failures and distant metastases despite WART. Therefore, the benefit of WART for advanced-stage disease is also questionable. Paclitaxel-based chemotherapy is currently being investigated in this setting.
authors.affiliation: Department of Radiation Oncology, Southwestern University, Dallas, Texas 75216, USA. NamPhong.Nguyen@med.va.gov
authors.forename: N P
authors.initials: NP
authors.lastname: Nguyen
authors.forename: S
authors.initials: S
authors.lastname: Sallah
authors.forename: U
authors.initials: U
authors.lastname: Karlsson
authors.forename: P
authors.initials: P
authors.lastname: Vos
authors.forename: A
authors.initials: A
authors.lastname: Ludin
authors.forename: D
authors.initials: D
authors.lastname: Semer
authors.forename: D
authors.initials: D
authors.lastname: Tait
authors.forename: M
authors.initials: M
authors.lastname: Salehpour
authors.forename: G
authors.initials: G
authors.lastname: Jendrasiak
authors.forename: C
authors.initials: C
authors.lastname: Robiou
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002291:Carcinoma, Papillary / Q000401:mortality* / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery; D016889:Endometrial Neoplasms / Q000401:mortality* / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D009657:North Carolina; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome